The 94.5% efficacy of the $MRNA vaccine is getting the headlines, but its stability at -20˚C (normal freezer) long term and up to 30 days at 4˚C (normal fridge) are game changers.
@SynthIge
I am the corresponding author of this study and what you claimed above is completely wrong . Not a single vaccinated individual in our study was noted to have developed a new "autoimmune disease." That is not what Fig. S4B shows.
Our lab's first paper () is now out at
@nature
. We found that the cytokine IL-18 can drive potent anti-tumor activity from the innate and adaptive immune system, but that its activity is restricted by a high-affinity "decoy receptor" IL-18BP. (1/)
With PhD and MD/PhD admissions season kicking into gear, I have deeply mixed feelings about recruiting the next generation of trainees into the biosciences. Many do not realize that the biotech industry is in grave danger with vast swathes of research jobs in jeopardy.
Is there a bigger scam than the requirement that labs have pay the university "tuition" for graduate students that are working full time in the lab (e.g., year 3 and up)? Why do the NIH and other funding agencies allow this? A pointless drain on research $$$ that makes no sense.
Resign
@CDCDirector
. The American people deserve better than your record of incompetence, negligence, and now blatant apathy. Your job is to protect the vulnerable, not to consign them to death. What would be "encouraging" is your retirement.
I'm astonished by how many people are buying the thinking that waiving vaccine IP will somehow magically increase vaccine supply. A patent is not a factory, personnel, a GMP process, and regulatory approval. It will take months to boot up even without supply chain shortages.
Does vaccination prevent these sequela? Well, the early data so far indicate that breakthrough infections in vaccinated people can still cause long-COVID. So those "mild" infections are probably not as benign as many are making them out to be.
The IL-18 armored CAR-T data from
@carlhjune
's group at ASH this year is remarkable (). 100% ORR so far, 7/8 patients had relapsed on a prior CAR-T product. IL-18 baby!!!
Today I asked the Yale administration to suspend or cancel the Blavatnik Fund for Innovation at Yale in response to Russia’s wanton attack on Ukraine. Despite his insistence otherwise, Len Blavatnik is an oligarch whose fortune came through his close ties to the Kremlin. (1/2)
How does primary SARS-CoV-2 infection compare to mRNA vaccination when it comes to autoantibody development?
@_BlueJay3
led an effort with
@VirusesImmunity
and her lab and our
@BRIseattle
collaborators to answer this question:
Bats, which host numerous RNA viruses like SARS-CoV without disease, have naturally decreased activity of NLRP3 (). Implies inflammasome may be a good CV19 target. Anyone know the status of the
@IFMThera
NLRP3 antagonist now at
@NovartisScience
?
Please check out our latest preprint led by
@Eric_Y_Wang
, Yile Dai, and
@connor_rosen
about a new autoantigen discovery platform that we developed called REAP (Rapid Extracellular Antigen Profiling):
(1/n)
Now that we are settled into our new digs at
@FredHutch
in Seattle, the Ring Lab is expanding! We have 2
#postdoc
positions and a research tech position open. See below for links. (1/4)
My lab and I have been thrilled to work with
@VirusesImmunity
and her lab on this project. This is our first debut into systems immunology using a new platform we developed called REAP. We'll have a lot more to say about REAP soon, but please check out Akiko's 🔥 Tweetorial below
New exciting collaboration work with
@Aaronmring
lab reveals diverse and functional autoantibodies in
#COVID
patients.
Our findings provide clues for why COVID affects many organs, induce range of symptoms that are long lasting.
Thread (1/n)
Ever wonder how microbes interact with the host at a molecular level? Check out our latest paper in
@nature
with Noah Palm and
@chuttenh
where we developed a host:microbe profiling technology, BASEHIT, to atlas interactions between commensal microbes and the human exoproteome.
Exchange between
@VirusesImmunity
and
@jbloom_lab
raises an emerging paradox in COVID-19. Neutralizing Abs are the long term solution to prevent disease, but there is concerning evidence that anti-SARS-CoV-2 antibodies may contribute to lethal immunopathology. (1/4)
Our latest host-microbiome interactions paper has now landed on the cover of
@nature
. Immense shoutout to Eric Smith for transforming our research into this breathtaking image. It’s truly a symbiosis of science and art!
Incredibly important preprint from
@awyllie13
and colleagues. Nasal antigen tests lag by DAYS in detecting omicron when there are infectious viral loads in saliva. This confirms the experience of many reported on Twitter comparing nasal to throat swabs.
Big update on
@SimchaTx
’s progress to advance the ‘decoy-resistant’ IL-18 program that we developed in my lab. I’m excited to say that the Phase 1 trial is underway and the company is now backed by a major investment from some phenomenal groups. Stay tuned!
#News
: Excited to share we’ve raised $40M in our series B financing and initiated our Phase 1/2 study to evaluate our first-in-class interleukin-18 variant in
#cancer
. Learn more here:
Nothing says "stick it to big pharma" more than rejecting a $20 vaccine and having to get a $2000 monoclonal antibody therapy instead. (Of course, both are "free" to patients with no OOP costs, but they cost all of us in the form of taxes and insurance premiums.)
5/ I can attest that, after this experience, I am even more dedicated to fighting against vaccine mandates. Instead of enriching the pockets of Big Pharma and corrupt bureaucrats and politicians, we should be advocating the monoclonal antibody infusion therapy.
I interviewed a magnificent MSTP applicant who is determined to become a surgeon scientist. They confided that other interviewers told them this is a naive ambition and that you can't be a surgeon and a scientist. Forgive me, but that is the dumbest @#$! I've ever heard.
I am getting a lot of emails and DMs from people wondering if our recent preprint raises concerns that a vaccine to SARS-CoV-2 would cause autoantibody responses like we see in COVID-19. I do not think that this is likely at all. (1/n)
PIs: if you have unrestricted funds to use, there is no better investment than to purchase KF94 and/or comfortable N95 masks for your lab members. For a lab of 10-12 people, we're talking a couple hundred dollars/month. We've been doing this since late August in my lab.
Super proud of my first grad student
@connor_rosen
who gave a killer thesis defense about his work to discover microbiota interactions with the human exoproteome. Connor is co-mentored by Noah Palm and connected our labs in a way we never could have imagined. Congrats Connor!!!
Not trying to call anyone out, but it is bitterly ironic to see folks from the anti-booster virtue signaling crowd now decrying that we haven't boosted enough. Look guys, you won, we are only 8% boosted heading into the winter at a high baseline. Now we're going to lose people.
@DGlaucomflecken
Well they negotiate rebates with drug companies, and then pocket the savings for themselves, with little benefit to the patient. It's a pretty sweet racket.
Want to profile immune responses to cancer
#immunotherapy
... in patients? We are seeking a
#postdoctoral
researcher to lead our translational studies of a novel cytokine we developed, 'decoy-resistant' IL-18, in its first-in-patient clinical trials.
I am deeply shocked and saddened by the senseless murder of Kevin Jiang. It is clear that he was a truly incredible person- the best of Yale. I cannot imagine the sorrow that his fiancee and mother are experiencing. If anyone is aware of a gofundme to support them, please post it
We owe our students and future colleagues the truth, not platitudes and false reassurance. And if you are passionate about innovation in biomedical research, now is the time to stand up and make your voice heard to protect the biotech industry.
Was on a zoom call today for the Yale COVID-19 Advanced Therapies Team. Inspired by the incredible leadership of Rick Bucala and
@KaminskiMed
. Residents of CT should know that Yale docs are working tirelessly to ensure that COVID-19 patients will get most cutting-edge treatments.
I am grateful for this award and want to credit
@YaleOCR
, the Blavatnik Fund for Innovation at Yale, and Gabrielle's Angel Foundation
@CureCancerNow
for providing key seed funding for this project. We will work as hard as we can to get this cytokine into clinical trials quickly.
The interim data for the current pediatric <12 vaccine trials needs to be released immediately. Let parents and pediatricians use their own judgement to consider off-label use. The FDA's insistence on powering trials to detect rare side effects is a major error, esp in light of Δ
IgA is likely the ideal format for COVID-19 passive immunization, but it is really hard to manufacture. Talked to IgA guru Noah Palm and he pointed me to this paper (). A simple fusion of a pIgR binding peptide to IgG enables trancytosis into BAL.
Christmas Miracle? A company just mistakenly sent us ~$12,000 of reagents (a year's supply rather than one month's). They said just keep it, gratis. Is this real life???!!! 🥳😎🤣
I have joined hundreds of leaders in biotech in a letter pledging to reject all investment and collaboration from Russian companies/funds and the industrial leaders who enable and embolden Putin. I urge my peers to add their voice to this call. (2/2)
Right now, we are in a golden era of biomedical innovation. Breakthroughs like mRNA vaccines and cancer immunotherapy will save millions of lives. Emerging technologies like CRISPR/gene-editing promise transformational therapeutics.
Bills like HR3 and similar provisions in the proposed $3.5T spending bill would absolutely devastate the biopharma industry. If passed, companies will have to dramatically cut R&D activities. This blow will predominantly hit scientists, with some estimating >200,000 jobs lost.
I am glad to have been wrong about mRNA vaccines in so many ways. Cost, toxicity, and cold-chain ended up being nothingburgers. We very close to the point in the US where vaccine supply is not limiting. So the multiple J&J/AZ fiascos are a blessing in disguise. mRNA is better.
Please check out our lab's AACR poster on a new antibody:antigen discovery platform focused on extracellular proteins. We found that patients treated with checkpoint inhibitors made novel functional autoantibodies to secreted proteins and surface receptors
There is no way academia can support the number of graduate students that we train. Thus, there is a very real possibility of a horrific job crisis for scientists. Hundreds of thousands of people will have degrees that are essentially worthless, despite decades of sacrifice.
Somewhat surprised to see reactions to the incredible new intravenous TB/BCG vaccine paper as "but it's only in macaques."
Wrong response... Next time try "OMG, they showed this in macaques?!!!" This is a huge deal.
Hopefully there won't be a
#justsayinmonkeys
hashtag.
Might I humbly suggest that we criticize papers based on their merits, and hold back the invective? You may not love a particular lab or journal (i.e., PNAS). But it's cruel to trainees to call their papers expletives and question their integrity.
Addendum: I regret my previous applications to this award. At the time, I was ignorant of the source of Blavatnik's wealth. This is not an excuse and I will no longer rely on the university to vet donors that support our research.
@EricTopol
@Nature
@VirusesImmunity
@YaleMed
@YaleIBIO
@EricTopol
Thank you so much for highlighting our work- we'll put out a tweetorial later. I just want to highlight that our findings are contemporaneous with an excellent paper from PJ Utz's group and that will be published soon in Nature Communications.
Multiple people have shared this GoFundMe link to support Kevin Jiang's memorial and to support his mother. It is being arranged by members of his church and dance group. Please donate if you can and RT.
I’m excited to share our story in
@CellCellPress
from
@aaronmring
, Erol Fikrig, Noah Palm,
@CarlyonLab
, and all the amazing collaborators! We used an interaction profiling system to map interactions between the human exoproteome and microbial pathogens.
We are getting incredible value w/these COVID vaccines. Every infection prevented saves the economy tens of thousands of $. The vaccines will save millions of lives. At <$100/pop, it's hard to accuse big pharma of opportunism. The public is getting the better end of the deal.
This is my professional twitter account, and I have endeavored to keep it focused on science and my lab. However there are times when we all must speak out in any and every forum we can. What is being done to the migrant children by the US Government is a crime and an atrocity.
"Drug pricing reform" policies like those pushed by Bernie don't solve the drug affordability problem. They will kill the most innovative sector of health care (biotech) to benefit the least innovative (insurance). Also, it would crush future job prospects for our PhD students.
Maybe it's just me, but I find it very off-putting when folks post their NIH priority scores/percentiles/screenshots of NOAs on twitter. It's great to share exciting news, but bragging about a grant score is frankly indecorous. Should we brag about our yearly directs too? C'mon
So yeah, a career in the biosciences rules... right now. But if you are thinking about graduate school in the near future, I strongly advise you to pay close attention to these bills in congress. If the music stops, good careers will end quickly and possibly permanently.
We are excited about the therapeutic potential of DR-18, and to that end, I recently started a company called Simcha Therapeutics to advance DR-18 into clinical trials. Right now, we are projecting the Phase I studies should begin in H1 of 2021. (16/)
@AndyBiotech
To be clear though, this was not a representative sampling. "The tests came from people in grocery and big box stores. Cuomo said this was important because it came from people who were out — not people isolating at home."
So probably capturing people at higher risk of exposure.
CNN just interviewed the first patient who received a SARS-CoV-2 vaccine (the $MRNA drug). High time we celebrate clinical trial volunteers and patients. Rockstars!!!
And industry is poised to be a huge driver of innovation. It's never been harder to get an R01 from NIH, but never been easier to raise tens of millions (or more!) for a new biotech start-up! I can speak to this from my first hand experience in both domains.
Serious lack of self-awareness of un-fireable tenured professors, some with pensions for life, telling trainees not to worry about job prospects if biotech goes belly-up. When job & financial security hasn't been on your mind for years, perhaps your "advice" is a bit suspect.
I remembered that there is a university scam almost as bad as tuition for grad students: Parking fees for grad students (and everyone else). Apparently universities believe it is equitable to take 3% (!!!) of post-tax income just for people to park their cars at work. WTF.
First and big points on the board for the Palm Lab! I love the strategy, using host receptors as a "lens" to understand microbes. We are excited to be collaborating with them in this area. Stay tuned for more from Noah, Haiwei, and
@connor_rosen
. PS Noah get on Twitter
Released online from Cell: Palm and colleagues screen human gut bacteria against an expansive range of GPCRs and identified dozens of bacteria that activate both well-characterized and orphan GPCRs |
#GPRome
#metabolome
#gutmicrobiota
My colleague
@Joshilabyale
is a phenomenal *MENTOR*, scientist, and human being. He knows a lot about great MENTORship because he learned from the very best during his own training. It gives me great joy to see him pay that forward to his lab members.
I am especially concerned that this crisis is going to hit right as the biosciences are becoming diverse than ever. Some of the most vulnerable and deeply-affected people will the very URM and women scientists that we just recruited into the STEM pipeline.
I often ask MSTP applicants what is their favorite paper they've read in the last year. Not trying to judge/score, just legit curious what gets them excited. Many name
@ericsongg
and
@VirusesImmunity
's paper on VEGF-C therapy in GBM. Love pointing out Eric is one of our MSTPs!
In med school, I saw Carol Dweck talk about the effect of mindset on performance. It was a mind-blowing paradigm shift for me and the growth mindset is a philosophy that I have embraced. Check it out- it's a simple change in your thinking that can have a huge impact.
Mechanistically, these results seem to decrease the likelihood that new AAbs seen with SARS-CoV-2 infection are due to 'molecular mimicry' against the spike protein, as the vaccinated patients develop excellent responses to spike as expected without AAbs.
To be clear, our results do not definitively rule out that mRNA vaccination can drive the formation of new AAbs. If that does occur, it is a relatively rare phenomenon compared to its high incidence with infection. Thus, mRNA vaccines 'decouple' AAb risk from SARS-CoV-2 immunity.
Drug affordability is a huge problem, but these misguided proposals are not acceptable solutions. There are better ways to alleviate the burden of out of pocket costs to patients- I recommend following
@PeterKolchinsky
and
@NPLB_org
to learn more.
Noah Palm and I are looking to recruit a jointly mentored
#postdoc
to discover causal
#hostmicrobe
interactions in Crohn's disease. We have developed new technologies to profile protein:protein and
#metabolite
:
#GPCR
interactions in very high-throughput. Please RT.
With the exciting news that there is likely an effective COVID-19 vaccine, we need to ramp up our mitigation efforts dramatically. The vaccine will be worthless if we all get infected before it can be widely administered. Hopefully this provides incentive for those who need it.
I can't stand seeing
@VP
talk over and interrupt both women on the stage tonight over and over and over again. It's beyond disrespectful. It's intentional.
In this report, we find that in both healthy individuals and patients with pre-existing autoimmune diseases, there is no detectable net increase in AAbs after mRNA vaccination using our REAP method.
Completely untrue! Large pharma corporations have capabilities (regulatory & marketing) that small biotech firms lack, and typically have NO desire to develop. They are passing the baton and exiting. Big pharma primes the pump for innovation with these M&A and licensing deals.
For years, Big Pharma has gobbled up small biotech firms that might otherwise force them to compete. As soon as these companies are acquired, innovation stops. The culture of creativity is killed. The small firm’s vision is lost, and the big firm’s profits become priority.
With ~20 kids dying of COVID every week in the US right now, we need Pfizer to release their pediatric trial data ASAP. Off-label use can save lives in the weeks it will take for the FDA to provide an EUA. Pediatricians can make their own evidence-based judgements earlier.
We and others previously found that SARS-CoV-2 infection is associated with the development of new autoantibodies (AAbs), with a trend towards increasing AAb levels with more severe infection.
PSA: antibodies are no longer that expensive/difficult to make. They are now routinely manufactured for <<$100/g. They can be extremely potent. Alternative scaffolds made in microbial systems are usually not cheaper/faster to manufacture. Esp. since most CDMOs specialize in CHO.
Think how much faster we could "open up" if everyone would just wear their mask (and wear it properly). Not to mention preventing so many senseless deaths. BTW, these graphs would be even more impressive drawn in linear, not log scale.
#COVID19
Important new study demonstrates why
#Masks4All
implementation is so urgent in this
#coronavirus
pandemic
“My mask protects you; your mask protects me.”